Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorHamilton Health Sciences Corporation
About this trial
Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
Eligibility criteria
Qualifiers
Age ≥18 years
Provide informed consent to participate.
Disqualifiers
Currently treated with and cannot withdraw colchicine due to medical necessity; or
Known allergy/sensitivity to colchicine; or
Prior self-reported intolerance to colchicine at a dose of 0.6 mg daily or lower; or
Currently pregnant or planning to become pregnant or breastfeed during the study; or
Trial design
Treatments tested in this trial
- Colchicine
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Hamilton Health Sciences Corporation
Lead sponsor
Hamilton Academic Health Sciences Organization
Collaborator
St. Joseph's Health Care London
Collaborator
Source ClinicalTrials.gov